Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. - van Asselt ADI; Armstrong N; Kimman M; Peeters A; McDermott K; Stirk L; Ahmadu C; Govers TM; Hoentjen F; Joore MA; Grimm SE (PharmacoEconomics, 2023)